Skip to main content
Premium Trial:

Request an Annual Quote

Pharmacopeia and Eos Call of Merger

NEW YORK, Jan. 18 - Call off the florists.


Pharmacopeia and Eos Biotechnology said late on Thursday that their boards have mutually agreed to kill the planned merger they announced last August.

"We remain optimistic about the future prospects of the science, technology and people at Pharmacopeia," said Joseph Mollica, chairman, president and CEO of Pharmacopeia.

"We believe there are many ways in which we can prosper by adding to and leveraging our existing biology and chemistry capabilities. We will continue to pursue the many alternatives available to us," said Mollica.

David Martin, president and CEO of Eos, added: "Eos has the people, technology, partners and vision to build a leading therapeutic development company. We will continue to move forward aggressively with our plans for other therapeutic candidates and look to partner when appropriate."

The Scan

Tens of Millions Saved

The Associated Press writes that vaccines against COVID-19 saved an estimated 20 million lives in their first year.

Supersized Bacterium

NPR reports that researchers have found and characterized a bacterium that is visible to the naked eye.

Also Subvariants

Moderna says its bivalent SARS-CoV-2 vaccine leads to a strong immune response against Omicron subvariants, the Wall Street Journal reports.

Science Papers Present Gene-Edited Mouse Models of Liver Cancer, Hürthle Cell Carcinoma Analysis

In Science this week: a collection of mouse models of primary liver cancer, and more.